Literature DB >> 27263740

The predictive value of stimulation index calculated by modified mixed lymphocyte culture in the detection of GVHD following hematopoietic stem cell transplantation.

Hülya Sayılan Şen1, Tülay Kılıçaslan Ayna, Hayriye Şentürk Çiftçi, Sevgi Kalayoğlu Beşışık, Emel Ayşe Onal, Arzu Akçay, Hülya Bilgen, Mehmet Gürtekin, Deniz Sargın, Mahmut Çarin.   

Abstract

OBJECTIVE: Mixed lymphocyte culture (MLC) is one of the routine tests performed prior to hematopoietic stem cell transplantation (HSCT) as a predictive assay for assessing the quality of donor matching and graft-versus-host disease (GVHD). The stimulation index is one of the formulas of the MLC test, and it is used for evaluation of matching between donor and recipient. Modified MLC (mMLC) test is produced by adding various cytokines to the MLC test, and increased sensitivity has been reported with this modification.
METHODS: The importance of the stimulation index values in MLC and mMLC tests was evaluated in 59 patients who received HSCs from human leukocyte antigen-identical sibling donors. In the mMLC test, cytokines were added as interleukin (IL)-2, IL-2 + IL-4 and IL-2 + interferon (IFN)-gamma + tumor necrosis factor (TNF)-alpha. Stimulation index values in mMLC test were compared with stimulation index values in MLC test.
RESULTS: Twenty-three (39%) patients developed GVHD. When evaluated in terms of stimulation index >1 patients, in MLC, 55% of the patients developed GVHD (p=0.229), whereas these values were 75% in the IL-2 added mMLC test (p=0.035), 100% in the IL-2 + IL-4 added mMLC test (p=0.076) and 85.7% in the IL-2 + IFN-gamma + TNF-alpha added mMLC test (p=0.015).
CONCLUSION: mMLC increased the sensitivity of the test. The relation between the positive results and evidence of GVHD after transplantation was found significant.

Entities:  

Year:  2010        PMID: 27263740     DOI: 10.5152/tjh.2010.48

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN: 1300-7777            Impact factor:   1.831


  1 in total

Review 1.  Osteopontin and Transplantation: Where Are We Now?

Authors:  Beata Kaleta
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-05-21       Impact factor: 4.291

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.